{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:44:07Z","timestamp":1790030647650,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T00:00:00Z","timestamp":1441670400000},"content-version":"vor","delay-in-days":464,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.jval.2014.01.008","type":"journal-article","created":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T12:50:17Z","timestamp":1399294217000},"page":"424-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Bazedoxifene versus Oral Bisphosphonates for the Prevention of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis at Higher Risk of Fracture: A Network Meta-Analysis"],"prefix":"10.1016","volume":"17","author":[{"given":"Alexandra G.","family":"Ellis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadi","family":"Chines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Sutradhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen P.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl.","key":"10.1016\/j.jval.2014.01.008_bib1","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1016\/S0002-9343(97)00415-4","article-title":"Osteoporosis: prevention, diagnosis, and management","volume":"102","author":"Deal","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.jval.2014.01.008_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jval.2014.01.008_bib3","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jval.2014.01.008_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","article-title":"Requirements for DXA for the management of osteoporosis in Europe","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jval.2014.01.008_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3310\/hta9220","article-title":"A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis","volume":"9","author":"Stevenson","year":"2005","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2014.01.008_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3310\/hta11040","article-title":"The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women","volume":"11","author":"Stevenson","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2014.01.008_bib7","unstructured":"European Medicines Agency. Assessment report for Conbriza. Procedure No. EMEA\/H\/C\/913. 2009. Available from: http:\/\/www.emea.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human \/medicines\/000913\/human_med_000723.jsp. [Accessed October 19, 2011]."},{"key":"10.1016\/j.jval.2014.01.008_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/CIA.S15711","article-title":"Efficacy and safety of bazedoxifene for postmenopausal osteoporosis","volume":"6","author":"Kawate","year":"2011","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jval.2014.01.008_bib9","unstructured":"FRAX. WHO Fracture Assessment Tool. Available from: http:\/\/www.shef.ac.uk\/FRAX\/. [Accessed October 19, 2011]."},{"key":"10.1016\/j.jval.2014.01.008_bib10","unstructured":"National Institute for Health and Care Excellence. The guidelines manual 2009. Available from: http:\/\/www.nice.org.uk\/aboutnice\/howwework\/developingniceclinicalguidelines\/clinicalguidelinedevelopmentmethods\/GuidelinesManual2009.jsp?domedia=1&mid=60B7B3CD-BBC2-E1BE-A6D53FD68D8845AD. [Accessed October 19, 2011]."},{"key":"10.1016\/j.jval.2014.01.008_bib11","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2014.01.008_bib12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2014.01.008_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2014.01.008_bib14","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2014.01.008_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1191\/096228001678227794","article-title":"Bayesian methods in meta-analysis and evidence synthesis","volume":"10","author":"Sutton","year":"2001","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jval.2014.01.008_bib16","series-title":"WinBUGS User Manual: Version 1.4","author":"Spiegelhalter","year":"2003"},{"key":"10.1016\/j.jval.2014.01.008_bib17","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jval.2014.01.008_bib18","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00198-005-1945-x","article-title":"Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies","volume":"16","author":"Boonen","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jval.2014.01.008_bib19","first-page":"265","article-title":"Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers","volume":"82","author":"Bone","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2014.01.008_bib20","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.01.008_bib21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jval.2014.01.008_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1185\/030079905X30752","article-title":"Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE","volume":"21","author":"Chesnut","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2014.01.008_bib23","first-page":"1535","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Fracture Intervention Trial Research Group. Lancet"},{"key":"10.1016\/j.jval.2014.01.008_bib24","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2014.01.008_bib25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jval.2014.01.008_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.01.008_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jval.2014.01.008_bib28","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2014.01.008_bib29","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group","volume":"85","author":"Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301514000163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301514000163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T10:24:48Z","timestamp":1538648688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301514000163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1098301514000163"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2014.01.008","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bazedoxifene versus Oral Bisphosphonates for the Prevention of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis at Higher Risk of Fracture: A Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2014.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}